61 related articles for article (PubMed ID: 11862426)
1. Gender difference in the pharmacokinetics and metabolism of VX-548 in rats.
Yu G; Zhou X
Biopharm Drug Dispos; 2024 Apr; 45(2):107-114. PubMed ID: 38573807
[TBL] [Abstract][Full Text] [Related]
2. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a partial STING agonist, competes for human STING activation.
Temizoz B; Shibahara T; Hioki K; Hayashi T; Kobiyama K; Lee MSJ; Surucu N; Sag E; Kumanogoh A; Yamamoto M; Gursel M; Ozen S; Kuroda E; Coban C; Ishii KJ
Front Immunol; 2024; 15():1353336. PubMed ID: 38533502
[TBL] [Abstract][Full Text] [Related]
3. Improved oral bioavailability in rats of SR13668, a novel anti-cancer agent.
Green CE; Swezey R; Bakke J; Shinn W; Furimsky A; Bejugam N; Shankar GN; Jong L; Kapetanovic IM
Cancer Chemother Pharmacol; 2011 May; 67(5):995-1006. PubMed ID: 20623225
[TBL] [Abstract][Full Text] [Related]
4. The
Kerins A; Koszyczarek M; Smith C; Butler P; Riley R; Madgula V; Naik N; Redinbo MR; Wilson ID
Xenobiotica; 2022 Aug; 52(8):904-915. PubMed ID: 36149349
[No Abstract] [Full Text] [Related]
5. Pharmacokinetics in mice and metabolism in murine and human liver fractions of the putative cancer chemopreventive agents 3',4',5',5,7-pentamethoxyflavone and tricin (4',5,7-trihydroxy-3',5'-dimethoxyflavone).
Cai H; Sale S; Britton RG; Brown K; Steward WP; Gescher AJ
Cancer Chemother Pharmacol; 2011 Feb; 67(2):255-63. PubMed ID: 20364427
[TBL] [Abstract][Full Text] [Related]
6. Effect of Dexketoprofen on the Disposition Kinetics of Moxifloxacin in Plasma and Lung in Male and Female Rats.
Erdogan T; Oguz H; Corum O
Curr Drug Metab; 2024 Jan; ():. PubMed ID: 38258775
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent.
Rayburn E; Wang W; Li M; Zhang X; Xu H; Li H; Qin JJ; Jia L; Covey J; Lee M; Zhang R
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1423-31. PubMed ID: 22367116
[TBL] [Abstract][Full Text] [Related]
8.
Kerins A; Butler P; Riley R; Koszyczarek M; Smith C; Cruickshank F; Madgula V; Naik N; Redinbo MR; Wilson ID
Xenobiotica; 2024 Jun; ():1-12. PubMed ID: 38794972
[No Abstract] [Full Text] [Related]
9. Gender Differences in Pharmacokinetics: A Perspective on Contrast Agents.
Courchesne M; Manrique G; Bernier L; Moussa L; Cresson J; Gutzeit A; Froehlich JM; Koh DM; Chartrand-Lefebvre C; Matoori S
ACS Pharmacol Transl Sci; 2024 Jan; 7(1):8-17. PubMed ID: 38230293
[TBL] [Abstract][Full Text] [Related]
10. [Not Available].
Heyer C
MMW Fortschr Med; 2024 Jun; 166(10):27. PubMed ID: 38806911
[No Abstract] [Full Text] [Related]
11. Evaluation of gender differences in the pharmacokinetics of oral zileuton nanocrystalline formulation using a rat model.
Muthumula CMR; Khare S; Jog R; Wickramaratne B; Lee A; Chakder S; Burgess DJ; Gokulan K
Int J Pharm X; 2024 Jun; 7():100254. PubMed ID: 38774112
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Drug Pharmacokinetic, Tissue Distribution and Excretion Profiles of the Novel Limonin Derivate HY-071085 as an Anti-Inflammatory and Analgesic Candidate in Rats and Beagle Dogs.
Dong L; Liu W; Zhao X; Yu F; Xu Y; Su M
Pharmaceuticals (Basel); 2022 Jun; 15(7):. PubMed ID: 35890101
[TBL] [Abstract][Full Text] [Related]
13. Bioavailability challenges associated with development of anti-cancer phenolics.
Gao S; Hu M
Mini Rev Med Chem; 2010 Jun; 10(6):550-67. PubMed ID: 20370701
[TBL] [Abstract][Full Text] [Related]
14. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhou S; Kestell P; Tingle MD; Paxton JW
Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.
Zhou S; Paxton JW; Kestell P; Tingle MD; Ching LM
Cancer Chemother Pharmacol; 2001 Apr; 47(4):319-26. PubMed ID: 11345648
[TBL] [Abstract][Full Text] [Related]
16. Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid.
Zhou S; Paxton JW; Tingle MD; Kestell P
Drug Metab Dispos; 2000 Dec; 28(12):1449-56. PubMed ID: 11095582
[TBL] [Abstract][Full Text] [Related]
17. Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice.
Zhou S; Kestell P; Paxton JW
J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Sep; 776(2):231-6. PubMed ID: 12138005
[TBL] [Abstract][Full Text] [Related]
18. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
Zhou S; Kestell P; Baguley BC; Paxton JW
Invest New Drugs; 2002 Aug; 20(3):281-95. PubMed ID: 12201491
[TBL] [Abstract][Full Text] [Related]
19. Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.
Zhou S; Kestell P; Paxton JW
Drug Metab Rev; 2002 Nov; 34(4):751-90. PubMed ID: 12487149
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
